Senostimulator Program
Oncology
Pre-clinicalActive
Key Facts
About Atropos Therapeutics
Atropos Therapeutics is a private, preclinical-stage biotech leveraging a novel understanding of cellular senescence to develop first-in-class therapeutics. The company's core innovation is the FATES platform, a phenotypic screening technology based on the detection of ATRX foci, which aims to identify 'senosuppressors' to prevent harmful senescence in aging and 'senostimulators' to induce beneficial senescence in cancer. With a seasoned leadership team and scientific advisory board, Atropos is positioned in the rapidly growing longevity and senotherapeutics space, though it faces significant technical and competitive risks inherent to pioneering a new drug discovery approach.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |